drugset / Trial / NCT00005960

Combination Chemotherapy in Treating Patients With Prostate Cancer That Has Not Responded to Hormone Therapy

NCT00005960 ↗

Phase 2 Unknown Amgen
Treatment

Summary

RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Giving more than one drug may kill more tumor cells. PURPOSE: Phase II trial to study the effectiveness of combination chemotherapy in treating patients who have prostate cancer that has not responded to hormone therapy.

Timeline

Start
1999-10
Primary completion
—
Completion
—

Drugs

EvaluationDrugModalityDoseRoute
Subject Cyclophosphamide Other / unclassified — Intravenous
Subject Docetaxel Small molecule — Intravenous
Subject Doxorubicin Other / unclassified — Intravenous
Background filgrastim Protein / enzyme biologic — Subcutaneous

Indications